Guobang Pharma released its 2026 interim report, with net profit attributable to the parent company at 341 million yuan, a decrease of 25.07% compared to the same period last year. Total operating revenue was 3.142 billion yuan, up 3.84% year-on-year, marking five consecutive years of growth. Net cash inflow from operating activities was 455 million yuan, a substantial increase of 342.23% year-on-year. The company's latest gross margin was 23.77%, down 3.08 percentage points from the same period last year, and ROE was 4.06%, down 1.59 percentage points.
Guobang Pharma LtdNet profit down 25.07% year-on-year, with lower gross margin and ROE.